Cargando…
Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy
BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy is a powerful adoptive immunotherapy against both B-cell malignancies and some types of solid tumors. Interleukin (IL) -15 is an important immune stimulator that may provide ideal long-term persistent CAR-T cells. However, higher base line o...
Autores principales: | Zhang, Ying, Zhuang, Qinghui, Wang, Fang, Zhang, Can, Xu, Chang, Gu, Aiqin, Zhong, William H., Hu, Yi, Zhong, Xiaosong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516829/ https://www.ncbi.nlm.nih.gov/pubmed/36167591 http://dx.doi.org/10.1186/s12967-022-03626-x |
Ejemplares similares
-
IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
por: Battram, Anthony M., et al.
Publicado: (2021) -
IL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin
por: Bellón, Teresa, et al.
Publicado: (2022) -
IL-15 in the Combination Immunotherapy of Cancer
por: Waldmann, Thomas A., et al.
Publicado: (2020) -
Heterodimeric IL-15 in Cancer Immunotherapy
por: Bergamaschi, Cristina, et al.
Publicado: (2021) -
Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus
por: Tosic, Vesna, et al.
Publicado: (2013)